XIIDRA

This brand name is authorized in Canada, United States

Active ingredients

The drug XIIDRA contains one active pharmaceutical ingredient (API):

1 Lifitegrast UNII 038E5L962W - LIFITEGRAST

Lifitegrast is a lymphocyte function-associated antigen-1 (LFA-1) antagonist. It binds to the integrin LFA-1, a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED. Read about Lifitegrast

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
XIIDRA Οphthalmic solution	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01XA25		S Sensory organs → S01 Ophthalmologicals → S01X Other ophthalmologicals → S01XA Other ophthalmologicals
Discover more medicines within S01XA25

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02471027
Country: US	FDA, National Drug Code	Identifier(s): 0078-0911, 54092-606